FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913173828> ?p ?o ?g. }

• W2913173828 abstract "Clinical studies treating pediatric and adult solid tumors such as glioblastoma (GBM) with a triple drug regimen of temozolomide (TMZ), bevacizumab (BEV), and irinotecan (IRI) [TBI] have demonstrated various efficacies, but with no unexpected toxicities. The TBI regimen has never been previously studied in recurrent GBM (rGBM) patients. In this retrospective study, we treated rGBM patients who had satisfactory bone marrow function with the TBI regimen. We identified 48 adult rGBM patients with a median age of 56 years (range: 26-76), who received Tumor Treating Fields (TTFields) treatment for 30 days or longer, and concurrent salvage chemotherapies. The patients were classified into two groups based on chemotherapies received: TBI (TBI+T, N=18) versus bevacizumab (BEV)-based chemotherapies (BBC+T, N=30). BBC regimens were either BEV monotherapy, BEV+IRI or BEV+CCNU. Patients in TBI+T group received on average 19 cycles of TMZ, 26 and 21 times infusions with BEV and IRI, respectively. Median overall survival (OS) and progression-free survival (PFS) for rGBM (OS-R and PFS-R) patients who received TBI+T were 18.9 and 10.7 months, respectively. In comparison, patients who received BBC+T treatment had OS-R and PFS-R of 11.8 (P>0.05) and 4.7 (P<0.05) months, respectively. Although the median PFS results were significantly different by 1.5 months (6.6 vs 5.1) between TBI+T and BBC+T groups, the median OS difference of 14.7 months (32.5 vs 17.8) was more pronounced, P<0.05. Patients tolerated TBI+T treatment well and there were no unexpected toxicities. The most common side effects from TBI+T treatment included grade III hypertension (38.9%) and leukopenia (22.2%). In conclusion, the TBI regimen might play a role in the improvement of PFS-R and OS-R among rGBM patients. Prospective studies with a larger sample size are warranted to study the efficacy and toxicity of TBI+T regimen for rGBM." @default.
• W2913173828 created "2019-02-21" @default.
• W2913173828 creator A5004681846 @default.
• W2913173828 creator A5012894954 @default.
• W2913173828 creator A5037755700 @default.
• W2913173828 creator A5040076309 @default.
• W2913173828 creator A5045792465 @default.
• W2913173828 creator A5049195015 @default.
• W2913173828 creator A5068252391 @default.
• W2913173828 creator A5089846740 @default.
• W2913173828 date "2019-01-31" @default.
• W2913173828 modified "2023-10-18" @default.
• W2913173828 title "Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study" @default.
• W2913173828 cites W1493427854 @default.
• W2913173828 cites W1536538430 @default.
• W2913173828 cites W1550004638 @default.
• W2913173828 cites W1671049130 @default.
• W2913173828 cites W1964560666 @default.
• W2913173828 cites W1973045287 @default.
• W2913173828 cites W1973211972 @default.
• W2913173828 cites W1976711535 @default.
• W2913173828 cites W1977392502 @default.
• W2913173828 cites W1978661277 @default.
• W2913173828 cites W1980170616 @default.
• W2913173828 cites W1980346956 @default.
• W2913173828 cites W2021787222 @default.
• W2913173828 cites W2032090704 @default.
• W2913173828 cites W2048342842 @default.
• W2913173828 cites W2058521348 @default.
• W2913173828 cites W2061061337 @default.
• W2913173828 cites W2069075549 @default.
• W2913173828 cites W2079015646 @default.
• W2913173828 cites W2096287682 @default.
• W2913173828 cites W2108923852 @default.
• W2913173828 cites W2121396361 @default.
• W2913173828 cites W2124736921 @default.
• W2913173828 cites W2125620300 @default.
• W2913173828 cites W2132697290 @default.
• W2913173828 cites W2136313288 @default.
• W2913173828 cites W2148923175 @default.
• W2913173828 cites W2149768128 @default.
• W2913173828 cites W2156330848 @default.
• W2913173828 cites W2165772224 @default.
• W2913173828 cites W2169869816 @default.
• W2913173828 cites W2170367762 @default.
• W2913173828 cites W2191764999 @default.
• W2913173828 cites W2205491921 @default.
• W2913173828 cites W2213386766 @default.
• W2913173828 cites W2234353674 @default.
• W2913173828 cites W2308575384 @default.
• W2913173828 cites W2436535122 @default.
• W2913173828 cites W2580731784 @default.
• W2913173828 cites W2587216924 @default.
• W2913173828 cites W2590390154 @default.
• W2913173828 cites W2606977905 @default.
• W2913173828 cites W2746529640 @default.
• W2913173828 cites W2767420169 @default.
• W2913173828 cites W2768388636 @default.
• W2913173828 cites W2776406960 @default.
• W2913173828 cites W2778283729 @default.
• W2913173828 cites W2889806273 @default.
• W2913173828 doi "https://doi.org/10.3389/fneur.2019.00042" @default.
• W2913173828 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6366009" @default.
• W2913173828 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30766509" @default.
• W2913173828 hasPublicationYear "2019" @default.
• W2913173828 type Work @default.
• W2913173828 sameAs 2913173828 @default.
• W2913173828 citedByCount "41" @default.
• W2913173828 countsByYear W29131738282019 @default.
• W2913173828 countsByYear W29131738282020 @default.
• W2913173828 countsByYear W29131738282021 @default.
• W2913173828 countsByYear W29131738282022 @default.
• W2913173828 countsByYear W29131738282023 @default.
• W2913173828 crossrefType "journal-article" @default.
• W2913173828 hasAuthorship W2913173828A5004681846 @default.
• W2913173828 hasAuthorship W2913173828A5012894954 @default.
• W2913173828 hasAuthorship W2913173828A5037755700 @default.
• W2913173828 hasAuthorship W2913173828A5040076309 @default.
• W2913173828 hasAuthorship W2913173828A5045792465 @default.
• W2913173828 hasAuthorship W2913173828A5049195015 @default.
• W2913173828 hasAuthorship W2913173828A5068252391 @default.
• W2913173828 hasAuthorship W2913173828A5089846740 @default.
• W2913173828 hasBestOaLocation W29131738281 @default.
• W2913173828 hasConcept C121608353 @default.
• W2913173828 hasConcept C126322002 @default.
• W2913173828 hasConcept C141071460 @default.
• W2913173828 hasConcept C143998085 @default.
• W2913173828 hasConcept C2776694085 @default.
• W2913173828 hasConcept C2777389519 @default.
• W2913173828 hasConcept C2777802072 @default.
• W2913173828 hasConcept C2780259306 @default.
• W2913173828 hasConcept C2780739268 @default.
• W2913173828 hasConcept C2780775027 @default.
• W2913173828 hasConcept C2781413609 @default.
• W2913173828 hasConcept C526805850 @default.
• W2913173828 hasConcept C71924100 @default.
• W2913173828 hasConceptScore W2913173828C121608353 @default.
• W2913173828 hasConceptScore W2913173828C126322002 @default.
• W2913173828 hasConceptScore W2913173828C141071460 @default.
• W2913173828 hasConceptScore W2913173828C143998085 @default.

• next